What are BTK inhibitors and how are they different from other therapies?
Produced in collaboration with CLL Society.
Support for this patient education program was provided by educational grants from AstraZeneca and Pharmacyclics.
In this virtual presentation, you can hear from a hematologist specializing in CLL, a nurse practitioner, and a CLL patient as they discuss what you need to know about BTK inhibitors (e.g. ibrutinib [Imbruvica], acalabrutinib [Calquence]). The esteemed panel addressed the audience’s questions, discussed complications, and revealed strategies to optimize management of your or your loved one’s CLL. After watching this program, you will be able to fully participate in shared decision-making regarding treatment choices, side-effect monitoring, and locating and using support resources.
During this 60-minute session, they:
- Identify key factors considered in selecting the right treatment for you or your loved one
- Engage with treatment teams in open dialogue to determine if BTK inhibitor treatment is right for you or your loved one’s CLL
- Discuss side effect management strategies with your treatment team
- Identify supportive resources for patients with CLL and their caregivers
Interested in learning more? Visit our CLL Patient Decision Library – Practicing with the Patient Voice.
What Matters in Treatment Decisions: Are you asking the right questions?
What side effects can I expect when using BTK inhibitors?
Cultivating Shared Decision-Making with your Treatment Team and Finding Support
Matthew S. Davids, MD, MMSC
Associate Professor of Medicine, Harvard Medical School
Matthew S. Davids, MD, MMSC, is an attending physician in the Lymphoma Program of the Division of Hematologic Malignancies and associate director of the CLL Center at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School in Boston. He has an active translational research program in chronic lymphocytic leukemia (CLL), studying Bcl-2 biology in his laboratory and leading clinical trials to evaluate a variety of novel therapeutic strategies in patients with CLL and other hematologic malignancies. Dr Davids received his medical degree from Yale School of Medicine in New Haven, Connecticut.
Josie Montegaard, MSN AGPCNP-BC
Nurse Practitioner, Dana-Farber Cancer Institute
Josie Montegaard, MSN AGPCNP-BC, is a nurse practitioner in the CLL Center at Dana-Farber Cancer Institute (DFCI) in Boston supporting Dr Jennifer Brown and Dr Matthew Davids. As the only advanced practice provider in the CLL Center at DFCI, she cares for over 40 CLL patients each week ranging from patients currently in observation to patients with multiply refractory disease and Richter’s transformations. Josie has been a sub investigator on many investigator-initiated clinical trials for CLL patients and serves as an educator for other nurses on management of patients with CLL by presenting updates in the field of CLL at conferences. She earned her master’s degree in nursing at Boston College where she graduated from the adult/gerontology nurse practitioner program with distinction.
Doreen Zetterlund is a non-profit project manager living in Southern California. She started her work in the non-profit arena in 2007 and began chronic lymphocytic leukemia (CLL) patient advocacy in 2015 to share all she has learned from her own CLL diagnosis. Doreen spends time volunteering at Leukemia & Lymphoma Society events, supporting group leaders at CLL Society meetings and events, and as a CLL patient advocate for the newly diagnosed. She also enjoys films, theatre, meditation, reading, and supporting the local humane society. Doreen is a native of Detroit, Michigan and graduated from Wayne State University with a Master of Fine Arts in communication and a bachelor’s degree in business management.